The role of JAK inhibitors in hematopoietic cell transplantation
Author:
Publisher
Springer Science and Business Media LLC
Subject
Transplantation,Hematology
Link
https://www.nature.com/articles/s41409-022-01649-y.pdf
Reference93 articles.
1. Morris R, Kershaw NJ, Babon JJ. The molecular details of cytokine signaling via the JAK/STAT pathway. Protein Sci. 2018;27:1984–2009. https://doi.org/10.1002/pro.3519.
2. Imada K, Leonard WJ. The Jak-STAT pathway. Mol Immunol. 2000;37:1–11. https://doi.org/10.1016/s0161-5890(00)00018-3.
3. Lin CM, Cooles FA, Isaacs JD. Basic mechanisms of JAK inhibition. Mediterr J Rheumatol. 2020;31:100–4. https://doi.org/10.31138/mjr.31.1.100. Suppl 1e-pub ahead of print 2020/07/18
4. Quintas-Cardama A, Verstovsek S. Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance. Clin Cancer Res. 2013;19:1933–40. https://doi.org/10.1158/1078-0432.CCR-12-0284.
5. Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway. J Cell Sci. 2004;117:1281–3. https://doi.org/10.1242/jcs.00963.
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. 99mTc‐labeled, tofacitinib citrate encapsulated chitosan microspheres loaded in situ gel formulations for intra‐articular treatment of rheumatoid arthritis;Drug Development Research;2024-08
2. A Novel JAK1 Inhibitor SHR0302 Combined With Prednisone for First-Line Treatment of Chronic Graft-Versus-Host Disease: A Phase I Clinical Trial;Cell Transplantation;2024-01
3. First Approval of Pacritinib as a Selective Janus Associated Kinase-2 Inhibitor for the Treatment of Patients with Myelofibrosis;Anti-Cancer Agents in Medicinal Chemistry;2023-07-10
4. Case report: Optimized ruxolitinib-based therapy in an infant with familial hemophagocytic lymphohistiocytosis type 3;Frontiers in Immunology;2022-11-23
5. Recent progress of JAK inhibitors for hematological disorders;Immunological Medicine;2022-10-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3